- All staff at Acerus Pharmaceuticals (TSX:ASP) are now working from home, in accordance with US and Canadian government guidelines
- Despite COVID-19 disruptions, the company is still working to progress various projects remotely
- Acerus is eagerly waiting to receive Health Canada’s approval of an erectile dysfunction treatment, Avanafil
- The company expects to release its first quarter results in May, but might have to reschedule if the pandemic persists
- Acerus Pharmaceuticals (ASP) remains steady at 4.5 cents per share
Acerus Pharmaceuticals (TSX:ASP) staff are now all working from home, in order to protect them from the ongoing COVID-19 pandemic.
The pharmaceutical company is abiding by guidelines from governments in both Canada and the US. However, the changes have severely limited the ability of sales staff to visit physicians.
Despite disruptions caused by the coronavirus, the company is still working to progress its various projects.
Acerus, with its US contract commercial provider, Syneos Health, is working to build out its US commercial and medical organisations. These includes marketing, sales, national accounts, and medical science liaisons.
Once built, the company will be ready to start promoting the hormonal medication Natesto, when business returns to normal.
Acerus has already made progress in returning Natesto to Canadian and South Korean markets. The company reportedly has enough of the active ingredient on hand to support global market restocking until early 2022.
Acerus’ President and CEO, Ed Gudaitis, admitted that the COVID-19’s ongoing impacts are unprecedented.
“We continue to look for ways to grow our global footprint for Natesto, especially in our core market, the United States.
Our highest priority is to ensure the safety of our employees and healthcare professional partners, while ensuring the stability of our supply chain,” he said.
COVID-19 has certainly caused major delays for supply chains across the globe.
However, Acerus’ supply chains and contract manufacturers are still active and supporting the company’s expansion efforts. In addition to progress with Natesto, Acerus also continues to support the return of Estrace to Canada’s market.
In the meantime, the company is eagerly awaiting approval from Health Canada, for the erectile dysfunction treatment, Avanafil. Acerus hopes to receive it within the next 60 to 90 days.
The company is expecting to release its first quarter’s results on Tuesday, May 12. However, if COVID-19 persists, a substitute release date will be announced.
Acerus has scheduled its annual shareholders’ meeting for Tuesday, June 23. The company will confirm the date and meeting details in its 2020 Management Information Circular
Acerus Pharmaceuticals (ASP) remains steady at 4.5 cents per share, as of 10:10am EST.